2-[5-(2-methoxy-phenoxy)-6-phenyl-sulphonylamino-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yloxy]-ethyl pyridin-2-ylcarbamate | 180384-61-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2-[5-(2-methoxy-phenoxy)-6-phenyl-sulphonylamino-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yloxy]-ethyl pyridin-2-ylcarbamate
• 英文别名: 2-[6-(benzenesulfonamido)-5-(2-methoxyphenoxy)-2-[2-(2H-tetrazol-5-yl)pyridin-4-yl]pyrimidin-4-yl]oxyethyl N-pyridin-2-ylcarbamate
• CAS: 180384-61-6
• 化学式: C₃₁H₂₆N₁₀O₇S
• 分子量: 682.676
• InChiKey: BVZCMUQSSNWXRU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  49
• 可旋转键数：
  14
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  227
• 氢给体数：
  3
• 氢受体数：
  15

反应信息

• 作为产物：
  描述：

  N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-benzenesulphonamide 生成 2-[5-(2-methoxy-phenoxy)-6-phenyl-sulphonylamino-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yloxy]-ethyl pyridin-2-ylcarbamate
  参考文献：
  名称：

  Sulfonamides

  摘要：

  式中A、B、R.sup.1 -R.sup.8如本文所述的化合物是内皮素抑制剂，可用于治疗与内皮素相关的疾病，如高血压。这些化合物的化学合成以及含有这些化合物的药物组合物也是有用的。

  公开号：

  US06004965A1

文献信息

• SULFONAMIDES
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP0799209B1

  公开（公告）日：2003-08-06
• US6004965A
  申请人：——

  公开号：US6004965A

  公开（公告）日：1999-12-21
• [EN] PHARMACEUTICAL AND VETERINARY USES OF ENDOTHELIN ANTAGONISTS<br/>[FR] UTILISATIONS PHARMACEUTIQUES ET VETERINAIRES D'ANTAGONISTES DE L'ENDOTHELINE ET APPLICATIONS ASSOCIEES
  申请人：TEXAS BIOTECHNOLOGY CORP

  公开号：WO2001049289A1

  公开（公告）日：2001-07-12

  Pharmaceutical and veterinary uses of endothelin antagonists are provided. In particular, methods of treatment of laminitis, such as equine and bovine laminitis, by administration of one or more endothelin antagonists are provided. Methods of treatment, prevention, or amelioration of one or more symptoms of menopause; osteoporosis and metabolic bone disorders; climacteric disorders including hot flushes or flashes, abnormal clotting patterns, urogenital discomfort and increased incidence of cardiovascular disease, and other disorders associated with the reduction in ovarian function in women; pre-eclampsia; and control and management of labor during pregnancy by administration of endothelin antagonists are also provided.